Table 1. Association of RAN and RANBP2 polymorphisms with neuroblastoma risk.
| Genotype | Cases (N=429) |
Controls (N=884) |
P a | Crude OR (95% CI) |
P | Adjusted OR (95% CI) b |
P b |
| RAN rs56109543 (HWE=0.587) | |||||||
| CC | 304 (70.86) | 620 (70.14) | 1.00 | 1.00 | |||
| CT | 118 (27.51) | 238 (26.92) | 1.01 (0.78-1.31) | 0.933 | 1.01 (0.78-1.31) | 0.942 | |
| TT | 7 (1.63) | 26 (2.94) | 0.55 (0.24-1.28) | 0.165 | 0.55 (0.24-1.29) | 0.168 | |
| Additive | 0.363 | 0.93 (0.74-1.16) | 0.504 | 0.93 (0.74-1.16) | 0.502 | ||
| Dominant | 125 (29.14) | 264 (29.86) | 0.787 | 0.97 (0.75-1.24) | 0.787 | 0.97 (0.75-1.24) | 0.781 |
| Recessive | 422 (98.37) | 858 (97.06) | 0.155 | 0.55 (0.24-1.27) | 0.161 | 0.55 (0.24-1.28) | 0.164 |
| RAN rs7132224 (HWE=0.289) | |||||||
| AA | 227 (52.91) | 479 (54.19) | 1.00 | 1.00 | |||
| AG | 170 (39.63) | 335 (37.90) | 1.07 (0.84-1.37) | 0.581 | 1.07 (0.84-1.36) | 0.596 | |
| GG | 32 (7.46) | 70 (7.92) | 0.97 (0.62-1.51) | 0.875 | 0.96 (0.62-1.51) | 0.870 | |
| Additive | 0.823 | 1.02 (0.85-1.22) | 0.828 | 1.02 (0.85-1.22) | 0.842 | ||
| Dominant | 202 (47.09) | 405 (45.81) | 0.665 | 1.05 (0.84-1.33) | 0.665 | 1.05 (0.83-1.32) | 0.680 |
| Recessive | 397 (92.54) | 814 (92.08) | 0.771 | 0.94 (0.61-1.45) | 0.771 | 0.94 (0.61-1.45) | 0.770 |
| RAN rs14035 (HWE=0.800) | |||||||
| CC | 285 (66.43) | 590 (66.74) | 1.00 | 1.00 | |||
| CT | 135 (31.47) | 263 (29.75) | 1.06 (0.83-1.37) | 0.635 | 1.06 (0.83-1.37) | 0.641 | |
| TT | 9 (2.10) | 31 (3.51) | 0.60 (0.28-1.28) | 0.187 | 0.60 (0.28-1.29) | 0.191 | |
| Additive | 0.338 | 0.96 (0.78-1.19) | 0.731 | 0.96 (0.78-1.19) | 0.727 | ||
| Dominant | 144 (33.57) | 294 (33.26) | 0.912 | 1.01 (0.79-1.30) | 0.911 | 1.01 (0.79-1.29) | 0.918 |
| Recessive | 420 (97.90) | 853 (96.49) | 0.164 | 0.59 (0.28-1.25) | 0.169 | 0.59 (0.28-1.26) | 0.173 |
| RANBP2 rs2462788 (HWE=0.194) | |||||||
| CC | 402 (93.71) | 810 (91.63) | 1.00 | 1.00 | |||
| CT | 27 (6.29) | 74 (8.37) | 0.74 (0.47-1.16) | 0.187 | 0.74 (0.47-1.16) | 0.188 | |
| TT | 0 (0.00) | 0 (0.00) | / | / | / | / | |
| Additive | 0.185 | 0.74 (0.47-1.16) | 0.187 | 0.74 (0.47-1.16) | 0.188 | ||
| Dominant | 27 (6.29) | 74 (8.37) | 0.185 | 0.74 (0.47-1.16) | 0.187 | 0.74 (0.47-1.16) | 0.188 |
| Combined effect of protective genotypes for RAN c | |||||||
| 0 | 394 (91.84) | 814 (92.08) | 0.073 d | 1.00 | 1.00 | ||
| 1 | 26 (6.06) | 38 (4.30) | 1.41 (0.85-2.36) | 0.186 | 1.41 (0.84-2.36) | 0.189 | |
| 2 | 5 (1.17) | 7 (0.79) | 1.48 (0.47-4.68) | 0.509 | 1.48 (0.47-4.70) | 0.507 | |
| 3 | 4 (0.93) | 25 (2.83) | 0.33 (0.11-0.96) | 0.041 | 0.33 (0.12-0.96) | 0.042 | |
| 0-2 | 425 (99.07) | 859 (97.17) | 1.00 | 1.00 | |||
| 3 | 4 (0.93) | 25 (2.83) | 0.028 | 0.32 (0.11-0.94) | 0.037 | 0.33 (0.11-0.94) | 0.038 |
OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.
a χ2 test for genotype distributions between neuroblastoma patients and controls.
b Adjusted for age and gender.
c Protective genotypes were rs56109543 TT, rs7132224 GG and rs14035 TT.
d For additive model.